Physiological Action of Progesterone in the Nonhuman Primate Oviduct.

The oviduct of women [ 20 ] and NHPs [ 4 ] is a tubular, seromuscular organ supported by the mesosalpinx, a portion of the broad ligament that anchors the uterus and oviduct to the body wall ( Figure 2 a). It is attached distally to the ovary and proximally to the lateral aspect of the uterine fundus. The fallopian tube consists of four anatomical regions based on tubular anatomy and distinct lumen histology [ 7 ]. These include the infundibulum ( Figure 2 a,b), ampulla ( Figure 2 a,c), and isthmus ( Figure 2 a,d), as well as the interstitial portion that passes through the myometrium wall. The infundibulum transitions into the ampulla, the longest part, and then to the isthmus of the oviduct. The inner mucosal layer of the tube is the endosalpinx, and the muscular layers are collectively called the myosalpinx. The lumen of the endosalpinx is continuous from the abdominal tubal ostium near the ovary to the uterine cavity. The most distal portion of the oviduct, the infundibulum, is funnel-shaped with a fimbriated end surrounding the abdominal tubal ostium. Unlike rodents and domestic species, primates have no distinct ovarian bursa, and one of the fimbrial folds is usually attached to the ovary. The endosalpinx of the infundibulum and ampulla is extensively folded ( Figure 2 b,c) and contains ciliated and secretory endothelial cells ( Figure 3 ). The myosalpinx of the ampulla consists of a thin inner circular layer of smooth muscle surrounded by an equally thin longitudinal muscle layer. The oviductal ampulla transitions into the most proximal portion of the oviduct, the isthmus. The isthmus has a thick circular smooth muscle layer that is continuous with the uterine myometrium. The cellular integrity of the endosalpinx in primates is dependent on ovarian hormones; ovariectomy results in almost complete atrophy of the endosalpinx epithelium of the infundibulum and ampulla. Interestingly, the isthmus portion of the tube is less responsive to hormonal cycles than the more distal ampulla and fimbria. The ciliated cells of the endosalpinx and smooth muscle of the myosalpinx contribute to the movement of gametes along the oviductal canal [ 21 ]. Folding and hypertrophy of the fimbria and ampulla are dependent on E 2 . Co-administration of E 2 with P 4 in ovariectomized monkeys suppresses E 2 -driven tubal hypertrophy [ 11 , 22 ]. The ciliated cells of the infundibular fimbria create a current of peritoneal fluid toward the oviductal ostium, facilitating oocyte passage into the tube. The binding of spermatozoa to the ciliated epithelium occurs in many species, including primates [ 23 , 24 , 25 , 26 ], to provide a reservoir for fertilization [ 27 , 28 ]. In contrast to the ampulla, the isthmic and intramural epithelium contains only four primary epithelial folds and is strikingly less ciliated and therefore appears less sensitive to the actions of E 2 and P 4. Myosalpinx contractions move the oocyte to the site of fertilization in the ampulla and the developing embryo toward the uterus [ 29 ].

Old World nonhuman primates experience approximately 28–31-day ovarian cycles with prolonged follicular and luteal phases similar to women. These cycles are a striking contrast to many other mammalian species [ 17 ]. Laboratory rodents, for instance (e.g., mice and rats), display a short 4–5-day estrous cycle due to the formation of short-lived corpora lutea [ 30 ]; domestic livestock species (sheep, goats, and cattle) display estrous cycles featuring a short follicular phase followed by a long luteal phase [ 31 ]; and some mammals (e.g., rabbits) have induced ovulation [ 32 ]. Some species of New World monkeys do not reliably menstruate. However, Old World NHPs (e.g., apes [ 33 ], baboons [ 34 ], macaques [ 35 ], and vervet [ 36 ]) display actual menstruation with cyclic shedding of the endometrial lining [ 2 , 17 , 19 ]. By convention, the start of the cycle (day 1) is the first day of detectable menses, marking the beginning of the cycle’s follicular phase. The average luteal phase in macaques, baboons, and women is 10 days long, with P 4 declining 24–48 h before menses. Historical studies extensively characterized circulating concentrations of ovarian steroid hormones throughout the menstrual cycle in women and NHPs, including the vervet, macaque, baboon, and chimpanzee [ 17 , 37 , 38 , 39 ]. Assay technologies have undergone remarkable advancements since many of these early studies. Over the past 50 years, our research center has assayed E 2 and P 4 levels in macaques with techniques including radioimmunoassay [ 40 , 41 ], automated electro-chemoluminescent assays [ 42 , 43 , 44 ], and liquid chromatography–tandem mass spectrometry (LC-MS/MS) [ 45 ]. Comparing these methods reveals that LC-MS/MS can provide greater assay sensitivity and thus improve hormone detection at low concentrations. However, at normal cycling levels, the patterns described in early studies [ 17 , 39 , 43 ] remain reasonably accurate and are worth briefly describing here. In macaques, early follicular phase (menstrual cycle day 1–8) serum levels of E 2 average approximately 50 pg/mL and gradually rise to 100 pg/mL 2–4 days before the day of peak luteinizing hormone (LH) preceding ovulation. There is a surge in E 2 to levels >350 pg/mL in response to the LH peak, followed by a rapid fall to about 25 pg/mL. Then, as the luteal phase proceeds, there is a second rise in E 2 back to approximately 50 pg/mL. As the corpus luteum regresses, P 4 and E 2 levels fall to near the detection threshold for most assays (10–20 pg/mL). Human and chimpanzee E 2 levels follow a similar pattern but trend slightly higher, with mid-luteal phase levels in the 100 pg/mL range [ 17 ]. This pattern of P 4 secretion is very similar among all primate species. Therefore, there is essentially a constant E 2 > 50 pg/mL level in primates throughout almost all of the menstrual cycle, except for a brief mid-cycle E 2 surge and a brief decline immediately preceding menstruation. Before ovulation in the cycle’s follicular phase, P 4 levels range from 0.1 to 1.0 ng/mL. A small but significant rise in serum P 4 coincides with the LH peak; then, as luteal formation occurs, levels in macaques rise to maximal values of 3–8 ng/mL. As observed with E 2 , in humans and chimpanzees, the luteal phase peak of P 4 can be three to four times higher than in macaques. In all Old World primates, three days before the onset of menstruation, serum levels of P 4 fall sharply to <1 ng/mL. This rapid fall in P 4 triggers menstruation [ 46 ].

Brenner and coworkers [ 11 ] rigorously examined the NHP oviduct in naturally cycling cynomolgus [ 35 ] and rhesus macaques [ 47 ] and compared the animals to ovariectomized monkeys treated with implants releasing E 2 and P 4 to produce controlled artificial cycles [ 48 ]. To characterize tubal morphology, they assessed epithelial cell height, the percentage of secretory and ciliated cells, and the abundance of mitotic cells and apoptotic cells, including the phagocytic macrophages containing apoptotic nuclear fragments. Cycle phase-associated apoptosis was also described for the epithelium of primates (macaques, baboons, and women) and non-primate mammals [ 49 , 50 , 51 ]. Brenner and colleagues examined the formation of cilia and cytologic features including extension secretory tips and the deciliation process in which the apical portions of the ciliated cells pinch off the cell bodies [ 52 ]. Their studies revealed that E 2 and P 4 are the only ovarian factors required to recapitulate regular cyclic changes in tubal histology identical to the natural menstrual cycle [ 4 , 11 ]. Ovariectomized animals displayed almost complete atrophy and loss of cilia in the epithelium of fimbriae and ampulla. Treatment of ovariectomized monkeys with E 2 alone stimulated epithelial differentiation into a ciliated and secretory state. However, the sequential exposure to E 2 followed by E 2 + P 4 resulted in epithelial regression to a non-ciliated and non-secretory state similar to ovariectomized, untreated animals. They defined eight morphological conditions associated with epithelial ciliation and secretory activity [ 11 ]. These stages are summarized in Table 1 . Figure 3 shows examples of the histology of the oviductal fimbria in the late follicular phase and the late luteal phase of the cycle. Luteal phase P 4 acts as a master regulator of the cyclic oviductal differentiation against a background of continuous E 2 . At the end of the luteal phase of the natural menstrual cycle, most of the epithelium of the fimbria and ampulla is cuboidal with very few ciliated and secretory cells. Then, in the follicular phase’s post-menstrual period, epithelium hypertrophies become columnar and ciliated, and secretory cells develop to dominate in the infundibular fimbria and ampulla. These cells increase to a maximum height near mid-cycle and then shrink to a minimal height again by the mid-late luteal phase. Ciliated cells appear to shrink more rapidly than the secretory cells, and the apices of the latter are projected well beyond the tips of the cilia during the latter part of the cycle [ 22 , 53 ]. In ovariectomized animals, 2–3 days of E 2 begin the process of oviductal differentiation into a ciliated and secretory state. The first evidence of deciliation and suppression of secretion often emerged within 48 to 72 h of the onset of P 4 treatment. The work of Verhage et al. [ 54 ] supported the view that the tubal epithelium of women undergoes cyclic changes similar to those of NHPs, and the epithelial cells attain their maximum height and degree of ciliation during the late follicular phase in both the fimbriae and the ampulla. It is noteworthy that some reports indicate a minimal change in the percentage ciliation during women’s cycle [ 55 ]. Those prior reports may not have fully appreciated the role of fallopian tube anatomy in the ciliogenic cycle and did not examine all tube sections. More recent studies in women confirmed these conclusions and added that an increase in epithelial mitotic activity occurred during the follicular phase when P 4 was almost undetectable. Moreover, in macaques, the timing of the oviductal stages is not precise ( Table 1 ). There is variability associated with tubal anatomy. These stages appear most intense in the oviductal fimbria, which is either the first to enter or the quickest to complete the ciliogenic process. The ampulla responds slightly slower to changes in the hormonal milieu when entering and completing the ciliated secretory state. When most cells near the lumen of the ampulla were regressing, a few ciliated and secretory cells could be identified that lagged behind the main population near the muscle wall. Oviductal secretions have long been proposed to support fertilization and early embryo development [ 56 ]. These secretions and the regulation by steroid hormones in non-primate species have been recently reviewed [ 7 ]. Verhage and coworkers were among the first investigators to address steroid hormone-dependent oviductal secretions in primates [ 57 ]. Their studies reported the presence of secretory granules at the apical tips of secretory cells in the baboon. The same group then characterized an oviduct-specific glycoprotein (OVGP1) as an estrogen-dependent secretory protein synthesized by non-ciliated oviduct epithelial cells in various species, including macaque baboon and human [ 58 , 59 , 60 ]. While OVGP1 has recently been reported for other tissues, including the macaque cervix [ 61 ] and ovarian cancer [ 62 , 63 ], it remains a primary hormonally regulated secretory product of oviductal epithelial cells. OVGP1 appears to be an estrogen-upregulated protein that P 4 and other pure progestins suppress, and pure PRAs reverse the effect of P 4 treatment. During the normal menstrual cycle, OVGP1 is highly expressed in the secretory epithelial cells of the oviduct during the proliferative phase and is significantly reduced after ovulation [ 64 ]. In artificially cycled macaques, OVGP1 is reduced in P 4 and levonorgestrel in the cervix [ 61 ] and oviduct. Expression of OVGP1 is a marker of P 4 action and conditions including endometriosis that results in P 4 resistance result in persistent oviductal OVGP1 expression [ 65 ]. Moreover, treatment of macaques with contraceptive levels of ZK137-316, a PRA compound similar to mifepristone, significantly increased OVGP1 protein in oviductal fluid [ 66 ].

Actions of steroid hormones to influence cellular function fall into two classifications: the slower classical genomic response and the rapid non-genomic response. The genomic actions of P 4 in target tissues are mediated through interactions with intracellular progesterone receptors (PGR; also called PR), ligand-activated transcription factors that belong to the nuclear receptor family [ 67 , 68 , 69 ]. This family of transcription factors includes estrogen receptors (ER, ESR1, and ESR2), androgen receptors (AR), mineralocorticoid receptors (MR, nuclear receptor subfamily 3 group C member 2/NR3C2), and glucocorticoid receptors (GR, nuclear receptor subfamily 3 group C member 1/NR3C1). These are referred to as “classical” steroid receptors in which steroid binding leads to a long-lasting but slowly emerging response [ 68 ]. The transcription factor PGR is expressed in all P 4 -responsive organs, including the reproductive tract, mammary glands, cardiovascular system, and the oviduct [ 70 , 71 , 72 , 73 , 74 ]. To stimulate this “classical” response, binding of P 4 to the ligand-binding domain of the PGR induces a conformational change that transforms the receptor from a static, non-DNA-binding configuration into one that activates gene transcription. This occurs by loss of associated (heat shock) proteins and dimerization of receptor moieties. The activated receptor–ligand complex can then activate the transcriptional machinery by direct action on regulatory motifs, most commonly at PGR response elements (PRE) sites, or by direct association of ligand-bound PGR with other transcription factors and coactivators [ 69 , 75 , 76 , 77 , 78 ]. Differences among fixation methodologies can greatly affect the outcome of ER and PGR localization by immunohistochemistry (IHC). For instance, studies of OCT-embedded cryosections of oviductal fimbria and ampulla of ovariectomized macaques revealed staining for ER and PGR localized to the nuclei of epithelial, underlying stromal cells and smooth muscles. However, staining of paraffin-embedded sections produced variable cytoplasmic plus nuclear localization. Since binding assays revealed that most of the ER and PR were recovered from the cytosol, IHC on cryosections was interpreted as indicating that PGR was rapidly translocated from the cytoplasm to the nucleus regardless of the hormonal state of the animal and interacted strongly with chromatin in the nucleus. It is noteworthy to mention that ESR-2 (ERβ) expression is reported for the oviduct of several mammalian species [ 7 ], but the role of ESR-2 during cyclic regulation in NHPs in unknown. It is worth mentioning that PGR exists in two primary isoforms (A and B) encoded by a single gene but with different initiation sites that permit transcription of either a large or short isoform [ 71 , 79 , 80 , 81 ]. The larger (PR-B) isoform contains an N-terminal fragment of 164 amino acids that is absent from the short (PR-A) isoform. Thus, PR-B exhibits three transcription-activating domains (AF-1, AF-2, and AF-3), whereas PRA contains only two (AF-1 and AF-2) [ 82 ]. The two PR isoforms have similar steroid hormone and DNA binding activities but have distinct functions depending on the cell type and context of the target gene promoter. PRB appears to be a stronger transcription activator than PRA [ 80 ]. Due to the structural overlap of the two PGR isoforms, assessing the localization of the two PGR isoforms in the oviduct has been challenging. One approach is to use differential immunostaining with antibodies directed against PR-B and PR-A plus PR-B as well as specific differential PCR approaches. Using this approach, researchers at the University of Edinburgh reported attenuated PR-B in human fallopian tubes during the luteal phase of the menstrual cycle and during ectopic pregnancy [ 83 ]. However, cyclic regulation of oviductal PR-A/PR-B isoforms has not been confirmed in NHP studies. Rapid, nongenomic actions of P 4 are also reported for the oviduct. These are mainly attributed to so-called “membrane” receptors or “non-classical” progesterone receptors that appear to activate cellular second messenger pathways [ 68 , 84 , 85 , 86 ]. Among the rapid actions of P 4 in the oviduct are the effects on ciliary beat frequency [ 87 , 88 , 89 ] and rapid alteration to spermatozoa motility [ 90 ]. Non-classical PRs include a family of membrane progestin receptors (mPRs) as well as the G-protein-coupled receptor (GPCR) family, which includes progesterone receptor membrane component (PGRMC), PGRMC1, and PGRMC2 [ 6 , 67 ]. The PGRMC family shares properties not associated with P 4, including a heme-binding domain related to some cytochromes. The mPRs were first reported in fish [ 85 , 91 , 92 ], and subsequently, five mPR subtypes (α, β, γ, δ, and ε) were identified [ 91 ] in a wide array of cell types in many mammalian species, including primates. The mPRs have no known homologies with GPCRs or nuclear PGRs, but are structurally related to adiponectin receptors and are classified as the progestin and adipoQ receptor (PAQR) superfamily. They display a predicted seven-transmembrane region and bind small steroid molecules, resulting in G-protein activation. However, the function of mPRs remains less clearly defined than that of the nuclear receptors [ 68 ]. This is largely due to a lack of data on the mPR steroid binding domains [ 93 ] and the absence of well-defined mPR modulators.

It is well recognized that the oviduct is an estrogen-responsive organ that expresses ERα (ESR1) and PGR. Interestingly, ESR2 (ERβ) is also expressed in human fallopian tube ciliated cells, but the role of ERβ in NHPs remains to be determined. ER (not specific to ESR1 or ESR2) and PGR abundance have been assayed in naturally cycling NHPs as well as in NHPs treated sequentially with E 2 and P 4 to create artificial menstrual cycles. The earliest research characterizing the abundance of PGR in the primate oviduct utilized radiolabeled steroid binding on human fallopian tube [ 94 ]. These were followed by NHP studies that employed steroid binding and exchange assays to estimate levels of estrogen receptor and PGR (e.g., specific binding) in tissue homogenates [ 11 , 95 ]. These assays often used radiolabeled R2858 (a nuclear ER ligand) and R5020 (a nuclear PGR ligand) to avoid the metabolism of estrogen and P 4 . The sum of specifically bound steroids to the nuclear and cytosolic fractions from the homogenates represented an estimate of total receptor abundance. Binding of labeled R2858 and of R5020 were found to be significantly elevated in ovariectomized animals treated with E 2 (or at mid-menstrual cycle) compared to hormone-depleted animals. This technique revealed that the oviduct’s differentiation into a fully ciliated and secretory endosalpinx epithelium was accompanied by significant increases in total ER and PGR [ 11 ]. Treatment of E 2 -primed monkeys with E 2 in combination with P 4 similar to the luteal phase resulted in significantly reduced levels of ER and PGR. In the case of ER, levels were reduced below those of ovariectomized untreated animals. Thus, ER and PGR expression were dependent on E 2 action. Moreover, average ER and PGR levels were lower in animals treated with a combination of E 2 and P 4 than those observed in ovariectomized untreated monkeys. Because treatment with P 4 alone failed to stimulate either ER or PGR, it was proposed that P 4 acted to antagonize the effects of E 2 on oviductal differentiation by suppressing ER levels below the threshold required to facilitate E 2 action. The overall relationship provided by classical binding assays appears to be more complex than was initially proposed. In concert with biochemical binding assays, cellular localization of ER and PGR by IHC on cryosections revealed that both cell and tissue type affected P 4 suppression of ER and PGR. In support of binding assay results, the abundance of cells with strong nuclear staining for both ER and PGR increased in the follicular phase (and after E 2 treatment) and decreased in the luteal phase (or after E 2 plus P 4 treatment). However, specific staining for epithelial ER and PGR were localized to the secretory epithelial cells, not the ciliated cells ( Figure 3 ). This represents a paradox in that E 2 and P 4 strongly affect the ciliated phenotype, but staining is minimal in the ciliated cells. How can the dramatic effects of both E 2 and P 4 on the ciliated cells occur when the ciliated cells lack or express minimal receptors for both steroids? Moreover, PGR staining was almost completely absent in the epithelium during the luteal phase or after P 4 treatment. This produces the question: How does P 4 maintain its effects while suppressing its own receptor? IHC revealed that strong ERα and PGR staining were present in stromal, smooth muscle, and secretory epithelial cells, suggesting that the effects of P 4 on ciliated cells may be indirect. In the luteal phase (or after P 4 treatment), ERα staining is retained in all the undifferentiated epithelial cells and in the underlying stromal cells, whereas PGR is minimal in the epithelium and retained (but noticeably less intense) in the stromal compartment. Therefore, one possibility is that the state of differentiation of the oviductal epithelium is mediated indirectly through soluble growth factors (or other unidentified mediators) secreted by ERα- and PGR-positive stromal cells. Moreover, stromal cells are separated from the epithelium by a definitive basement membrane, which could reduce the influence of soluble factors. One potential mediator of P 4 progesterone action, particularly in PR-negative cells, is the presence of specific mPRs or other non-classical PRs reported for human, murine, bovine, and canine oviducts, as well as ovarian cancers that may be of tubal origin. Oviductal mPR (beta and gamma) have been localized to bovine, human, and mouse ciliated epithelial cells [ 96 ] and may mediate the rapid effect of P 4 on cilia beat frequency. However, localization of mPRs to oviductal cilia does not appear to reflect expected cyclic changes in ciliated cell abundance [ 96 ], as observed in nonhuman primates. Cyclic PGRMC1 and PGRMC2 expression and localization are reported for the macaque endometrium, but cyclic regulation in the NHP oviduct has not been extensively studied. The absence of reliable mPR/PGRMC modulators has significantly limited the study of these pathways in NHP models. In contrast, the expression and cellular action of nuclear PGR in the mammalian oviduct have been studied extensively.

The characterization of nuclear PGR isoforms has prompted the development of synthetic compounds called progesterone receptor modulators (PRMs) [ 97 ]. These include synthetic P 4 analogs (progestins) and P 4 antagonists (anti-progestins; PRAs) that bind to PGR and either stimulate or block PGR function [ 98 , 99 , 100 ]. It is noteworthy that long-term treatment with P 4 and synthetic progestins reduces the abundance of ciliated cells in NHPs [ 101 ], and short-term treatment decreases cilia beat frequency in human oviductal cultures [ 102 ]. Mifepristone (RU486), the first well-characterized PRA, acts as a glucocorticoid receptor antagonist in the primate uterus, opposing various estrogen effects. The action of PRMs is often unique to the target organ, cell type, and sometimes the animal model examined. This has led to tissue-selective or physiologically selective PRMs [ 98 ]. The nuclear action of PRMs on classical (genomic) action of P 4 has been most extensively evaluated because of the pharmaceutical potential of these compounds to treat gynecological disorders [ 97 , 98 , 99 , 103 ]. Compared to nuclear receptors, the action of PRM on mPRα, mPRβ, and mPRγ appears less clearly defined, with reports ranging from the minimal binding of mPRs to synthetic PRMs, especially classical PGR antagonists such as mifepristone [ 93 , 104 ], to putative or predictable actions [ 105 ]. Moreover, much of the studies on the nuclear action of PRMs have been conducted on non-primate models with strikingly different hormone profiles. In vivo assessments of mPR actions are confounded by co-expression of nuclear PGRs in many of the responsive cell types. However, differential binding of synthetic ligands offers the potential development of mPR-selective agonists and antagonists [ 93 ]. We have treated rhesus macaques with an array of potent PRAs including mifepristone [ 106 , 107 ], ZK 137 316 [ 108 , 109 ], ZK 230 211 [ 110 ], and CDB 2914 (Ulipristal) [ 111 ]. However, the primary experimental goal of these studies was to evaluate the action of these compounds on the uterine endometrium. Driving these studies was the observation that some PRA compounds, including mifepristone, have been reported to have unexpected anti-estrogenic actions on the endometrium. However, in the oviduct, pure PRA compounds such as ZK 230-211 appear to lack antiestrogen effects and block the genomic action of P 4 [ 106 , 107 ]. In this condition, the estrogen action is unopposed, and the oviducts appear in a fully differentiated and ciliated secretory state. PRMs can also provide contraception. Levonorgestrel is a contraceptive progestin that has inhibitory actions on oviductal cilia beat frequency and ovulation. Ulpristral and levonorgestrel have potential as emergency contraception, presumably by blocking ovulation. However, a secondary target may include oviductal cilia function. In vitro, progesterone can decrease human oviductal ciliary beat frequency (CBF) and muscular contractions, and the inhibitory effect of progesterone on CBF can be antagonized by mifepristone, a progesterone receptor (PR) modulator. Treatment of cycling rhesus monkeys with low-dose ZK 137-316, a compound very similar to mifepristone [ 112 ], prevented pregnancy at low doses that allowed menstrual cycles [ 113 ]. However, low-dose ZK 137-316 did not block ovulation and failed to alter oviductal differentiation and sperm passage but did significantly increase oviductal fluid levels of OVGP1 [ 66 ]. In contrast, ulipristal acts as a mixed agonist–antagonist compound and could disrupt gamete passage. This outcome on sperm passage may be PRA dose-dependent because other reports indicate that both ulipristal and mifepristone reduce ciliary beat frequency and contractility in human oviductal explants [ 114 ]. As indicated above, blockade of P 4 action in NHPs is not associated with well-defined tubal abnormalities. Treatments with pure PRA, including ZK137-316 [ 112 ], mifepristone, and ZK 230-211, result in a fully ciliated and secretory tubal epithelium. This is not abnormal for the proliferative phase of the cycle. However, tubal abnormalities such as ectopic pregnancy are almost nonexistent in NHPs compared to women. Reproductive tract infections occur in NHPs and appear to be affected by estrogen and P 4 action on the cervix, endometrium, and oviduct [ 115 ]. It can be speculated that treatment with mixed-action PRM therapy could alter normal cyclic changes. However, this represents a knowledge gap and further studies are required to assess the impact of P 4 modulation on tubal dysfunction in NHP models.

Several reviews address the action of ovarian steroid hormones on the mammalian reproductive tract [ 1 , 2 , 3 , 4 , 5 , 6 ]. It is well documented that estrogen (estradiol; E 2 ) is essential for the normal development of reproductive tract organs and regulating cell proliferation and metabolism of tract tissues. Progesterone (P 4 ) is also a crucial reproductive hormone with roles in the cyclic regulation of the fallopian tube [ 7 , 8 , 9 , 10 , 11 ], uterus [ 4 , 12 ], and cervix [ 13 ], as well as in supporting embryo implantation [ 14 ] and the maintenance of pregnancy [ 15 ]. Specific progesterone receptors mediate these actions, and synthetic progesterone receptor modulators (PRMs) are a class of drugs that alter P 4 effects and have clinical utility as contraceptives and in treating P 4 -associated disorders [ 16 ]. The menstrual cycles of women and nonhuman primates (NHPs) are strikingly different from the estrous cycles of most laboratory animals [ 17 ]. Therefore, NHPs provide valuable animal models for translational studies relating to women’s health [ 18 ]. However, most literature reviews overlook the specific actions of P 4 on the fallopian tube of NHPs. Therefore, our focus here is to describe the effect of P 4 on the oviduct, highlighting the current state of knowledge on NHPs. We begin this discussion with a brief overview of primate oviductal anatomy and histology during the menstrual cycle because the cyclic pattern of ovarian steroid secretion in women and NHPs is strikingly different from many mammals [ 19 ]. Our goal is not to discuss all historical studies, as these were addressed in previous reviews [ 4 , 11 , 20 ]. Like most mammals, primates have elevated levels of E 2 in the follicular phase and elevated P 4 in the luteal phase of the cycle. However, the primate corpus luteum also expresses high aromatase levels and secretes E 2 in addition to P 4 in the luteal phase [ 2 ]. Therefore, in primates, the cyclic changes in P 4 , not E 2 , drive cycles of epithelial differentiation in the fallopian tube ( Figure 1 ).

The role of P 4 in modulating oviductal morphology and physiology is indisputable. Cyclic changes in circulating P 4 against a background of E 2 stimulate changes in ciliary beating, muscular contraction, and oviductal fluid volume and composition, and, over time, suppress oviductal differentiation. These actions are mediated via intracellular nuclear receptors and via novel membrane receptors. However, the specific roles for membrane receptors remain to be resolved. Complicating these action mechanisms is that both classical nuclear receptors and fast-acting membrane receptors may be present in the same target cells. Thus, P 4 can have rapid and long-lasting actions by stimulating paracrine factors that mediate hormone responsiveness. There is a large gap in our knowledge regarding P 4 -regulated effectors in the oviduct, although prostaglandins, endothelins, and growth factors may have roles as critical secondary mediators. Further development of selective PRMs that specifically target membrane receptors versus nuclear receptor isoforms may be required to elucidate the complex cyclic regulation of the primate oviduct.